Preterm Infant Formula Carotenoid Supplementation Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Preterm infants lack sufficient carotenoids in their diet, leading to increased inflammation and oxidative stress due to underdeveloped organs and nutritional disadvantages, which existing formulas fail to adequately address.
Innovation Solution
A preterm infant formula supplemented with specific levels of lutein, lycopene, and beta-carotene, administered to modulate inflammation by decreasing plasma levels of C-reactive protein, a known inflammation marker.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If preterm infants are fed standard formula, then they receive basic nutrition, but they lack sufficient carotenoids leading to increased inflammation and oxidative stress
Solution Approach 1:
The patent applies parameter changes by modifying the carotenoid composition parameters in preterm infant formula. Specifically, it sets lutein at 20-50 μg/kg/day, lycopene at 10-30 μg/kg/day, and beta-carotene at 10-30 μg/kg/day, which are optimized ranges to reduce inflammation and oxidative stress while providing adequate nutrition for preterm infants.
Solution Approach 2:
The patent uses composite materials by combining multiple carotenoid compounds (lutein, lycopene, and beta-carotene) in specific proportions within the formula. This composite approach provides synergistic antioxidant and anti-inflammatory effects that single carotenoids cannot achieve alone, addressing the complex nutritional needs of preterm infants.
2Ease of operation
If preterm infants are deprived of carotenoids, then formula feeding is simpler, but inflammation markers such as C-reactive protein increase
Solution Approach 1:
The patent applies self-service by incorporating carotenoids directly into the infant formula during manufacturing, eliminating the need for separate supplementation or complex preparation steps by caregivers. The formula is ready-to-use with optimized carotenoid content, maintaining ease of administration while reducing inflammation markers through adequate carotenoid intake.
3Object-affected harmful factors
If carotenoid levels are increased in formula, then inflammation is reduced, but the complexity of formula composition increases
Solution Approach 1:
The patent applies local quality by providing different carotenoid compositions tailored specifically to preterm infant needs rather than using a universal formula. The specific carotenoid profile (lutein 20-50 μg/kg/day, lycopene 10-30 μg/kg/day, beta-carotene 10-30 μg/kg/day) is optimized for the unique physiological requirements of preterm infants, reducing inflammation without unnecessarily complicating the formula for other populations.
Data Source
AI summary
The present disclosure relates to preterm infant formulas comprising lutein, lycopene, and beta-carotene, and the use of the preterm infant formulas to modulate inflammation, such as skin inflammation, in preterm infants. Also disclosed are methods of modulating the level of C-reactive protein in a preterm infant using preterm infant formulas comprising mixtures of carotenoids.